Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

BusinessWire_EN 
0 0 19.07.24
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
 

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.

Interested participants can dial (866) 682-6100 or (862) 298-0702 (toll-free U.S. Canada). The audio webcast can also be accessed here. A replay of the webcast will be available on Aurinia’s website.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta, its U.S. commercial office is in Rockville, Maryland. The Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240719692619/en/

Aurinia Pharmaceuticals Inc. Stock

€5.12
-0.700%
Aurinia Pharmaceuticals Inc. shows a slight decrease today, losing -€0.036 (-0.700%) compared to yesterday.
Based on 7 Buy predictions and 5 Sell predictions the sentiment towards Aurinia Pharmaceuticals Inc. is rather balanced.
As a result the target price of 7 € shows a positive potential of 36.83% compared to the current price of 5.12 € for Aurinia Pharmaceuticals Inc..
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!